Big Increase in PFS With Maintenance Olaparib for BRCA+ Ovarian Cancer

Eric Pujade-Lauraine, MD, PhD

Patients with relapsed, platinum-sensitiveBRCA-mutant ovarian cancer experienced a 13.6-month improvement in progression-free survival (PFS) with the PARP inhibitor olaparib versus placebo, according to data reported at the Society of Gynecologic Oncology meeting.

The median investigator-assessed PFS was 19.1 months with olaparib compared with 5.5 months for placebo (HR, 0.30; 95% CI, 0.22-0.41;P<.0001). In a prespecified analysis of PFS by blinded central review committee, there was a 24.7-month PFS improvement. In this analysis, the median PFS was 30.2 months for the olaparib group versus 5.5 months for placebo, a 75% reduction in the hazard for progression and death (HR, 0.25; 95% CI, 0.18-0.35;P<.0001).

&ldquo;The progression-free survival benefit was supported by a significant delay in time to first subsequent therapy, second progression-free survival, and time to second subsequent therapy,&rdquo; said Eric Pujade-Lauraine, MD, PhD, of the University of Paris Descartes. &ldquo;With the exception of anemia, toxicity was mostly low grade. SOLO2 is the first phase III trial of olaparib tablets as maintenance treatment and showed a significant benefit in patients with platinum-sensitive, relapsed ovarian cancer andBRCA1/2mutation.&rdquo;

The results confirmed and extended those of a phase II trial that demonstrated a PFS advantage for olaparib maintenance therapy in relapsed, platinum-sensitive ovarian cancer (N Engl J Med. 2012;366:1382-1392). The earlier study did not select patients on the basis ofBRCAstatus, and patients received a different formulation of olaparib.

Although the earlier trial showed a PFS benefit in the overall population and across various subgroups, patients withBRCA-mutated ovarian cancer had the most prolonged PFS. Additionally, the capsule formulation of olaparib used in the phase II trial required patients to take as many as 16 pills a day. The 300-mg tablet formulation reduced the pill burden to 2 per day.

Pujade-Lauraine reported findings from the phase III SOLO2 trial that evaluated the efficacy and tolerability of a 300-mg tablet formulation of olaparib as maintenance therapy. Eligible patients had relapsed ovarian cancer, confirmedBRCA1/2mutation, and were in response to their most recent platinum-containing regimen following 2 or more prior systemic regimens.

Investigators in the multicenter international trial randomized patients 2:1 to olaparib 300 mg BID or to matching placebo. Treatment continued until disease progression. The primary endpoint was investigator-assessed PFS. The trial protocol included a sensitivity analysis of PFS, performed by a blinded independent central review committee. Secondary endpoints included second PFS (PFS2), overall survival, and safety and tolerability.

Data analysis included 294 randomized patients who received the assigned study treatment. Baseline characteristics did not differ substantively between treatment groups, as 53% to 54% of patients in each group had attained a partial remission at enrollment; 40% of each group had a platinum-free interval of 6 to 12 months; and about 40% of patients had received 3 or more prior lines of therapy.

The secondary endpoint of median time to first subsequent therapy or death was 27.9 months with olaparib and 7.1 months with placebo (P<.0001). The median PFS2 had yet to be reached in the olaparib group, whereas the placebo group had median of 18.4 months, representing a 50% reduction in the hazard ratio in favor of the PARP inhibitor (P= .0002). Time to second subsequent therapy or death also had yet to be reached in the olaparib arm compared with a median of 18.2 months in the placebo group (P<.0001). Data remained too immature for an analysis of overall survival.

Pujade-Lauraine said olaparib was generally well tolerated, as no new or unexpected treatment-associated adverse events (AEs) occurred in patients who received the PARP inhibitor. The most common AEs of any grade were nausea (75.9% vs 33.3%), fatigue/asthenia (65.6% vs 39.4%), anemia (43.6% vs 8.1%), vomiting (37.4% vs 19.2%), and diarrhea (32.8% vs 20.2%). Neutropenia occurred in 19.5% of the olaparib group versus 6.1% of the placebo group, and thrombocytopenia in 13.8% versus 3.0%.

Grade &sup3;3 AEs included anemia (19.5% vs 2.0%), neutropenia (5.1% vs 4.0%), and thrombocytopenia (1.0% in both groups).